<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[BAVA:Most promising in the field.]]></title><description><![CDATA[<p dir="auto">A victory with the potential to change investor perception and alter clinical practice could come from Bavarian Nordic's Prostvac for prostate cancer, which NCI's Schlom cited as one of the most promising in the field.</p>
<p dir="auto">Hvis Prostvac køre igennem,så er "The Sky is the limit"</p>
<p dir="auto">Link:Reuter</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/437274/bavamost-promising-in-the-field</link><generator>RSS for Node</generator><lastBuildDate>Mon, 27 Jul 2026 00:08:34 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/437274.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 16 May 2013 04:58:35 GMT</pubDate><ttl>60</ttl></channel></rss>